|
1
|
Van Den Neste E, Schmitz N, Mounier N,
Gill D, Linch D, Trneny M, Bouadballah R, Radford J, Bargetzi M,
Ribrag V, et al: Outcomes of diffuse large B-cell lymphoma patients
relapsing after autologous stem cell transplantation: An analysis
of patients included in the CORAL study. Bone Marrow Transplant.
52:216–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jurinovic V, Kridel R, Staiger AM,
Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper
W, Zelenetz AD, et al: Clinicogenetic risk models predict early
progression of follicular lymphoma after first-line
immunochemotherapy. Blood. 128:1112–1120. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schuster SJ, Svoboda J, Chong EA, Nasta
SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V,
Landsburg D, et al: Chimeric antigen receptor T cells in refractory
B-cell lymphomas. N Engl J Med. 377:2545–2554. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang C, Thudium KB, Han M, Wang XT, Huang
H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al: In
vitro characterization of the anti-PD-1 antibody nivolumab,
BMS-936558, and in vivo toxicology in non-human primates. Cancer
Immunol Res. 2:846–856. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Annibali O, Crescenzi A, Tomarchio V,
Pagano A, Bianchi A, Grifoni A and Avvisati G: PD-1 /PD-L1
checkpoint in hematological malignancies. Leuk Res. 67:45–55. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naidoo J, Page DB, Li BT, Connell LC,
Schindler K, Lacouture ME, Postow MA and Wolchok JD: Toxicities of
the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann
Oncol. 26:2375–2391. 2015.PubMed/NCBI
|
|
8
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martelli M, Ferreri AJ, Agostinelli C, Di
Rocco A, Pfreundschuh M and Pileri SA: Diffuse large B-cell
lymphoma. Crit Rev Oncol Hematol. 87:146–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kochenderfer JN, Dudley ME, Kassim SH,
Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ,
Hughes MS, Sherry RM, et al: Chemotherapy-refractory diffuse large
B-cell lymphoma and indolent B-cell malignancies can be effectively
treated with autologous T cells expressing an anti-CD19 chimeric
antigen receptor. J Clin Oncol. 33:540–549. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Batlevi CL, Matsuki E, Brentjens RJ and
Younes A: Novel immunotherapies in lymphoid malignancies. Nat Rev
Clin Oncol. 13:25–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davila ML, Riviere I, Wang X, Bartido S,
Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska
M, et al: Efficacy and toxicity management of 19-28z CAR T cell
therapy in B cell acute lymphoblastic leukemia. Sci Transl Med.
6:224–225. 2014. View Article : Google Scholar
|
|
13
|
Jaspers JE and Brentjens RJ: Development
of CAR T cells designed to improve antitumor efficacy and safety.
Pharmacol Ther. 178:83–91. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang AC, Postow MA, Orlowski RJ, Mick R,
Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al: T-cell
invigoration to tumour burden ratio associated with anti-PD-1
response. Nature. 545:60–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li S, Siriwon N, Zhang X, Yang S, Jin T,
He F, Kim YJ, Mac J, Lu Z, Wang S, et al: Enhanced cancer
immunotherapy by chimeric antigen receptor-modified T cells
engineered to secrete checkpoint inhibitors. Clin Cancer Res.
23:6982–6992. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zou W, Wolchok JD and Chen L: PD-L1
(B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms,
response biomarkers, and combinations. Sci Transl Med. 8:328–324.
2016. View Article : Google Scholar
|
|
17
|
Läubli H, Balmelli C, Bossard M, Pfister
O, Glatz K and Zippelius A: Acute heart failure due to autoimmune
myocarditis under pembrolizumab treatment for metastatic melanoma.
J Immunother Cancer. 3:112015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brudno JN and Kochenderfer JN: Toxicities
of chimeric antigen receptor T cells: Recognition and management.
Blood. 127:3321–3330. 2016. View Article : Google Scholar : PubMed/NCBI
|
